- Editorial
13 Citations
6,916 Views
4 Pages
Special Issue: Nanobody
- Patrick Chames and
- Ulrich Rothbauer
Since their first description in 1993 [...]
- 2.7Impact Factor
- 4.5CiteScore
- 23 daysTime to First Decision
Antibodies, Volume 9, Issue 1
March 2020 - 6 articles
Cover Story: Hybridoma screening is a tedious and challenging task. Several pitfalls can lead to false positives, which might be identified as poor quality, but not before an in-depth validation has been performed. Hence, the best clones must be identified as early as possible, ideally in the first screening step. This novel, microarray-based method enables the user to screen a vast number of clones with a very selective and sensitive assay. Only high quality antibodies are detected as positive. One or several inhibition assays can be performed in parallel that directly confirm the utility of the clones in competitive immunoassays. View this paper.
- Issues are regarded as officially published after their release is announced to the table of contents alert mailing list .
- You may sign up for email alerts to receive table of contents of newly released issues.
- PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.
Articles (6)
- Article
13 Citations
8,823 Views
17 Pages
Human IgA Monoclonal Antibodies That Neutralize Poliovirus, Produced by Hybridomas and Recombinant Expression
- Rama Devudu Puligedda,
- Vladimir Vigdorovich,
- Diana Kouiavskaia,
- Chandana Devi Kattala,
- Jiang-yang Zhao,
- Fetweh H. Al-Saleem,
- Konstantin Chumakov,
- D. Noah Sather and
- Scott K. Dessain
Poliovirus (PV)-specific intestinal IgAs are important for cessation of PV shedding in the gastrointestinal tract following an acute infection with wild type or vaccine-derived PV strains. We sought to produce IgA monoclonal antibodies (mAbs) with PV...
- Article
5 Citations
4,339 Views
10 Pages
Equal Neutralization Potency of Antibodies Raised against Abrin Subunits
- Yoav Gal,
- Anita Sapoznikov,
- Reut Falach,
- Ohad Mazor,
- Ron Alcalay,
- Eytan Elhanany,
- Moshe Aftalion,
- Sharon Ehrlich,
- Chanoch Kronman and
- Tamar Sabo
Abrin and ricin are potent AB toxins, which are considered biological threats. To date, there are no approved treatments against abrin or ricin intoxications. Previously, we showed that the administration of polyclonal anti-abrin antibodies to mice t...
- Editorial
1 Citations
3,684 Views
2 Pages
Acknowledgement to Reviewers of Antibodies in 2019
- Antibodies Editorial Office
The editorial team greatly appreciates the reviewers who have dedicated their considerable time and expertise to the journal’s rigorous editorial process over the past 12 months[...]
- Review
101 Citations
22,017 Views
27 Pages
Antibody Conjugates-Recent Advances and Future Innovations
- Donmienne Leung,
- Jacqueline M. Wurst,
- Tao Liu,
- Ruben M. Martinez,
- Amita Datta-Mannan and
- Yiqing Feng
Monoclonal antibodies have evolved from research tools to powerful therapeutics in the past 30 years. Clinical success rates of antibodies have exceeded expectations, resulting in heavy investment in biologics discovery and development in addition to...
- Article
13 Citations
10,261 Views
16 Pages
Antibody Screening by Microarray Technology—Direct Identification of Selective High-Affinity Clones
- Martin Paul and
- Michael G. Weller
The primary screening of hybridoma cells is a time-critical and laborious step during the development of monoclonal antibodies. Often, critical errors occur in this phase, which supports the notion that the generation of monoclonal antibodies with hy...
Get Alerted
Add your email address to receive forthcoming issues of this journal.
Antibodies - ISSN 2073-4468